



Catabasis Pharmaceuticals Announces Promotion of Ted Hibben to Chief Business Officer

CAMBRIDGE, MA, February 17, 2017 – [Catabasis Pharmaceuticals, Inc.](#) (NASDAQ: CATB), a clinical-stage biopharmaceutical company, today announced the promotion of Ted Hibben to Chief Business Officer. Mr. Hibben has more than 20 years of experience in business and corporate development, strategy, fundraising and M&A. Mr. Hibben joined Catabasis in 2015 and previously served as Senior Vice President, Corporate Development.

“Ted has a successful track record of building value with innovative product platforms, an ideal fit for our SMART linker platform. The SMART linker platform has already produced product candidates in multiple disease areas, creating opportunities for licensing as well as collaboration,” said Jill C. Milne, Chief Executive Officer of Catabasis. “Ted has been a significant contributor to the Catabasis executive team and we look forward to his further leadership in the Chief Business Officer role and his impact on our corporate strategy.”

Prior to joining Catabasis, Mr. Hibben was Senior Vice President, Corporate Development at Ensemble Therapeutics, where he formed four multi-target discovery and development-stage collaborations with pharmaceutical companies, generating over \$1 billion in potential milestone payments for programs emerging from Ensemble’s macrocycle library platforms. Previously, Mr. Hibben was Chief Business Officer at Cequent Pharmaceuticals, where he played an instrumental role in its 2010 merger with MDRNA, Inc. (now Marina Biotech), and was Vice President, Business Development and Alliance Management at Coley Pharmaceutical Group, where he sourced and/or managed nine development alliances and led the sale of Coley to Pfizer in 2008. Ted holds an MBA from Harvard University and an AB from Dartmouth College.

About Catabasis

At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our SMART (Safely Metabolized And Rationally Targeted) linker drug discovery platform enables us to engineer molecules that simultaneously modulate multiple targets in a disease. We are applying our SMART linker platform to build an internal pipeline of product candidates for rare diseases and plan to pursue partnerships to develop additional product candidates. For more information on the Company's drug discovery platform and pipeline of drug candidates, please visit www.catabasis.com.

###

Corporate and Media Contact

Andrea Matthews

Catabasis Pharmaceuticals, Inc.

T: (617) 349-1971

amatthews@catabasis.com